Scarica l'app Stockscreener
9.53
27.90%
-3.74
Precedente Chiudi:
$13.27
Aprire:
$11.12
Volume 24 ore:
432.71K
Relative Volume:
6.48
Capitalizzazione di mercato:
$617.93K
Reddito:
-
Utile/perdita netta:
$-9.60M
Rapporto P/E:
-3.0158
EPS:
-3.16
Flusso di cassa netto:
$-8.96M
1 W Prestazione:
+64.40%
1M Prestazione:
+51.87%
6M Prestazione:
+50.44%
1 anno Prestazione:
+18.12%
Intervallo 1D:
$9.46
$11.81
Intervallo di 1 settimana:
$5.885
$25.58
Portata 52W:
$4.9176
$25.58
Artelo Biosciences Inc Stock (ARTL) Company Profile
Nome
Artelo Biosciences Inc
Settore
Industria
Telefono
858-925-7049
Indirizzo
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Confronta ARTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
9.53 | 617.93K | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
536.19 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.22 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
552.58 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.50 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-02-12 | Iniziato | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Borsa (ARTL) Ultime notizie
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decline in Short Interest - Defense World
Artelo Biosciences IncRegains Nasdaq Minimum Bid Price Compliance - MarketScreener
Artelo Biosciences (NASDAQ:ARTL) Stock Rating Lowered by D Boral Capital - Defense World
Trading Halted for Artelo Biosciences (ARTL) as Investors Await News | ARTL Stock News - GuruFocus
Artelo Biosciences Engineers Reverse Stock Split - mg Magazine
# Artelo Biosciences announces 6-for-1 reverse stock split By Investing.com - Investing.com South Africa
# Artelo Biosciences announces 6-for-1 reverse stock split - Investing.com Australia
Artelo Biosciences (ARTL) Downgraded to Hold by D. Boral Capital - GuruFocus
Artelo Biosciences stock rating cut to Hold by D. Boral Capital - Investing.com Canada
Artelo Biosciences (ARTL) Downgraded to Hold by D. Boral Capital | ARTL Stock News - GuruFocus
This UnitedHealth Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Artelo Biosciences to Implement 6-for-1 Reverse Stock Split; Shares Down - marketscreener.com
Artelo Biosciences (ARTL) Downgraded to Hold Following Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Initiates 6-for-1 Reverse Stock Split - GuruFocus
Artelo Biosciences (ARTL) Initiates 6-for-1 Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences Announces Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences, Inc. Announces 6-for-1 Reverse Stock Split to Comply with Nasdaq Listing Requirements - Nasdaq
Artelo Biosciences Announces Reverse Stock Split - The Manila Times
Artelo Sets 6-for-1 Reverse Split for June 13: Key Details on Share Consolidation Plan - Stock Titan
Artelo Biosciences (NASDAQ:ARTL) Receives “Buy” Rating from D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Receives Continued 'Buy' Rating from D. Boral Capital | ARTL Stock News - GuruFocus
Artelo Biosciences presents promising OA pain treatment data By Investing.com - Investing.com South Africa
Artelo Biosciences (ARTL) Highlights New FABP Inhibitor Data at British Pain Conference | ARTL Stock News - GuruFocus
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study - The Manila Times
Artelo Biosciences presents promising OA pain treatment data - Investing.com
Non-Opioid Pain Drug Shows Breakthrough Results: Matches Popular Painkiller Naproxen in Major Study - Stock Titan
Artelo Biosciences (NASDAQ:ARTL) Stock Price Down 3.7% – Should You Sell? - Defense World
ARTL: Potential of Fabp Inhibitors in Treating Mood Disorders Hi - GuruFocus
Independent Study Confirms Breakthrough Potential of Artelo's Novel Anxiety DrugPhase 1 Data Coming - Stock Titan
Artelo Biosciences Reports Q1 2025 Financial Results - TipRanks
Artelo Biosciences Faces Nasdaq Compliance Challenge - TipRanks
ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Artelo Biosciences (ARTL) Expected to Announce Earnings on Monday - Defense World
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Reports Promising Psoriasis Treatment Advances | ARTL Stock News - GuruFocus
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models - AOL.com
Artelo Biosciences Announces Publication of New Peer-Reviewed Re - GuruFocus
Artelo Biosciences Reports Positive Effects Of ART26.12 In Psoriasis Models - Nasdaq
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis | ARTL Stock News - GuruFocus
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis - The Manila Times
Artelo Biosciences Announces Positive Preclinical Results for Psoriasis Treatment ART26.12 in Journal of Investigative Dermatology - Nasdaq
Breakthrough Oral Psoriasis Treatment Matches Current Drugs in New Research, Phase 1 Results Coming - Stock Titan
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Grows By 58,220.0% - Defense World
Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus
Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ARTL stock touches 52-week low at $0.85 amid market challenges - Investing.com
D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Artelo Biosciences Inc Azioni (ARTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):